Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant mussel adhesive protein
- Development stage
- Unknown
- Lead developer
- Denovahis Medical Technology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Recombinant mussel adhesive protein (rMAP) is a biomimetic recombinant protein inspired by the natural adhesive proteins secreted by the foot gland of marine mussels (such as *Mytilus edulis* or *Mytilus galloprovincialis*). Produced via genetic engineering in microbial hosts (such as *Escherichia coli* or yeast), rMAP is rich in tyrosine residues that can be post-translationally modified (e.g., via tyrosinase) to form 3,4-dihydroxyphenylalanine (DOPA). This structure endows the protein with strong wet adhesion, film-forming, antioxidant, anti-inflammatory, and antibacterial properties. It is primarily developed for wound healing, skin barrier repair, and cosmetic applications. In clinical trials, it is evaluated as a hydrogel dressing (often combined with laser therapies) for skin photoaging, solar lentigo, and actinic lentigo. Key developers include Juyou (Zhanyan) Bio-Technology and its research platform Denovahis, as well as other synthetic biology companies like Shenzhen Baiyin Biotechnology.
- Brand names
- JuyouZhanyan
- Other names
- rMAPrecombinant MAPrecombinant mussel foot proteinsr-Mussel Oligopeptide-1sr-贻贝寡肽-1
02
Targets
COL1 (Collagen type I)
Beyond the preview
Go deeper on recombinant mussel adhesive protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant mussel adhesive protein.